CEO & Founder, BioSure (UK)
There are 38 million people infected with HIV globally but only 14 million know. Tackling this disparity – and helping the people affected by it – is BioSure’s goal.
BioSure offers the world’s first HIV self-test using blood. It allows users to discreetly determine their HIV status at a time and place that is convenient for them. It has an accuracy rate of 99.7%. Founder and CEO Brigette Bard developed the kit based on the benefits afforded by home pregnancy tests – convenience and privacy.
This disruptive technology is fuelling fast growth at the business; annual revenue currently exceeds £1 million and the company in addition to South Africa, will soon begin exporting to Brazil. “Apart from the commercial opportunity we are evidencing enormous social impact and have a role to play in the UN’s plan to eradicate HIV by 2030,” says Brigette.
She is well-known for her commitment to and passion for self-testing, which allows people to make informed choices and assume responsibility for their healthcare. She is actively and dynamically involved in normalising the conversation around HIV, breaking down stigma and nurturing understanding around sexual health.